The Department of Veterans Affairs National Acquisition Center awarded an indefinite delivery contract to Exelan Pharmaceuticals Inc. to provide ibuprofen tablets and repackaging services in support of the VA's pharmaceutical programs. Exelan, a foreign-owned for-profit pharmaceutical company, has been awarded multiple delivery orders valued at over $1.5 million to repackage and deliver ibuprofen to the VA's national repackaging facility in Boca Raton, Florida. The orders are placed against existing IDIQs and blanket purchase agreements held by Exelan, enabling the VA to obtain a steady supply of this essential generic medication for distribution to VA medical centers and health programs serving veterans. No set-aside designations were applied to these firm fixed price awards, which range in completion from July 2022 through June 2025. This contract supports the VA's goal of providing affordable pharmaceuticals to veteran beneficiaries through the agency's Pharmacy Repackaging Program.
Exelan's long-standing experience as a pharmaceutical supplier to federal healthcare agencies like the VA, DoD, and Indian Health Service has positioned the company as a trusted provider of generic drugs and repackaging expertise to government customers. The ibuprofen delivery orders leverage Exelan's existing IDIQs and BPAs to consolidate and repackage bulk drug product into patient-ready units, ensuring a reliable supply of this common pain reliever for the VA's healthcare initiatives. The awards further demonstrate the VA's commitment to collaborating with private industry to enhance the efficiency and cost-effectiveness of its pharmaceutical supply chain to better serve the medical needs of the nation's veterans.
Generated 5/3/24, 9:06 AM